Profile data is unavailable for this security.
About the company
EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS, formerly known as Eczacibasi Ilac Sanayi ve Ticaret A.S., (EIS) is a Turkey-based company active in the pharmaceutical industry through its subsidiaries, affiliates and joint ventures. Its product portfolio consists of drugs for human health, veterinary drugs and personal care products, such as body and facial creams, hair gels, deodorants and various other products. The Company is also engaged in real estate development and construction through its subsidiary, Eczacibasi Gayrimenkul Gelistirme ve Yatirim A.S., formerly known as Eczacibasi Insaat ve Ticaret A.S. Its subsidiaries also include Eczacibasi Ilac Ticaret A.S. (EIT), EHP Eczacibasi Health Care Products Joint Stock Co. (EHP), and Eczacibasi Gayrimenkul Gelistirme ve Yatirim A.S., among others. EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S. is a member of Eczacibasi Group of Companies.
- Revenue in TRY (TTM)6.48bn
- Net income in TRY2.74bn
- Incorporated1951
- Employees1.12k
- LocationEIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret ASBuyukdere Cad. Ali Kaya Sok. No:5 LeventISTANBUL 34394TurkeyTUR
- Phone+90 2 123508000
- Fax+90 2 123508533
- Websitehttps://www.eis.com.tr
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Formycon AG | 2.72bn | 2.65bn | 27.32bn | 238.00 | 9.41 | 1.41 | 10.05 | 10.04 | 4.70 | 4.70 | 4.84 | 31.32 | 0.0891 | 104.80 | 3.56 | 326,453.80 | 8.69 | 5.87 | 9.33 | 6.33 | 30.00 | 28.54 | 97.55 | 39.76 | 0.9621 | -0.0189 | 0.0176 | 0.00 | 82.83 | 12.47 | 110.59 | 60.58 | 81.87 | -- |
| Abivax SA | 0.00 | -5.17bn | 28.19bn | 40.00 | -- | 4.11 | -- | -- | -3.35 | -3.35 | 0.00 | 3.12 | 0.00 | -- | -- | 0.00 | -73.79 | -65.49 | -96.88 | -94.75 | -- | -- | -- | -- | -- | -8.05 | 0.2206 | -- | -- | -- | -111.52 | -- | -19.06 | -- |
| Swedencare AB (publ) | 7.36bn | 217.99m | 28.41bn | 552.00 | 130.31 | 1.20 | 24.30 | 3.86 | 0.4505 | 0.4505 | 15.21 | 48.80 | 0.2412 | 2.35 | 9.52 | 4,966,461.00 | 0.7144 | 1.38 | 0.7361 | 1.43 | 55.64 | 55.34 | 2.96 | 5.10 | 1.82 | 2.21 | 0.1746 | 45.33 | 27.48 | 88.16 | -37.96 | 20.24 | 30.90 | -- |
| Eckert & Ziegler SE | 8.95bn | 1.20bn | 33.11bn | 1.07k | 27.13 | 3.96 | 19.44 | 3.70 | 1.65 | 1.44 | 12.27 | 11.29 | 0.5834 | 3.08 | 4.72 | 237,931.20 | 7.98 | 8.50 | 9.75 | 10.23 | 48.42 | 48.61 | 13.68 | 14.00 | 2.24 | 21.89 | 0.1919 | 35.09 | 10.74 | 7.84 | -2.84 | 13.22 | 33.82 | -30.12 |
| Calliditas Therapeutics AB | 4.00bn | -1.60bn | 36.77bn | 219.00 | -- | 90.41 | -- | 9.20 | -9.78 | -9.78 | 24.43 | 2.24 | 0.7541 | 3.16 | 8.97 | 6,723,169.00 | -30.19 | -26.46 | -38.05 | -30.27 | 95.01 | -- | -40.03 | -76.59 | 2.62 | -3.99 | 0.8943 | -- | 50.32 | -- | -13.08 | -- | -- | -- |
| BioGaia AB | 3.96bn | 1.13bn | 37.64bn | 211.00 | 34.52 | 5.91 | 31.19 | 9.49 | 3.68 | 3.68 | 12.88 | 21.47 | 0.5414 | -- | -- | 6,192,767.00 | 15.46 | 15.47 | 16.82 | 16.93 | 73.32 | 73.30 | 28.55 | 27.70 | -- | -- | 0.00 | 104.42 | 17.44 | 11.81 | -2.25 | 11.20 | 29.27 | 28.10 |
| EIS czcbs lc Sn v Fnnsl Ytrmlr Sny v Tcr | 6.48bn | 2.74bn | 37.76bn | 1.12k | 13.78 | 1.08 | 11.51 | 5.83 | 4.00 | 4.00 | 9.46 | 50.85 | 0.1578 | 3.00 | 4.85 | -- | 6.67 | 8.82 | 7.16 | 9.40 | 33.76 | 32.94 | 42.29 | 58.23 | 1.14 | -- | 0.0813 | -- | 86.94 | 56.41 | -8.16 | 62.73 | 141.59 | 31.51 |
| Polypeptide Group AG | 11.37bn | -1.80bn | 38.09bn | 1.20k | -- | 2.84 | -- | 3.35 | -1.54 | -1.54 | 9.71 | 11.45 | 0.5137 | 2.31 | 5.08 | 267,669.90 | -8.13 | 2.59 | -10.37 | 3.26 | 2.81 | 23.73 | -15.83 | 4.58 | 1.12 | -1.56 | 0.2466 | 15.79 | 14.60 | 12.36 | -762.29 | -- | 25.40 | -- |
| AddLife AB | 29.87bn | 240.85m | 40.42bn | 2.29k | 173.53 | 2.65 | 13.02 | 1.35 | 0.6483 | 0.6483 | 80.41 | 42.38 | 0.7393 | 3.62 | 5.53 | 4,258,149.00 | 0.6112 | 5.31 | 0.9299 | 8.83 | 37.16 | 36.89 | 0.8267 | 5.79 | 0.4778 | 1.48 | 0.5173 | 31.73 | 6.62 | 31.30 | -60.42 | 8.00 | 44.43 | -1.89 |
| FAES Farma SA | 16.24bn | 3.32bn | 41.28bn | 1.75k | 12.17 | -- | 10.32 | 2.54 | 0.3066 | 0.3066 | 1.50 | -- | -- | -- | -- | 265,361.00 | -- | 13.07 | -- | 15.20 | 66.19 | 64.10 | 20.36 | 19.79 | -- | -- | -- | -- | 2.83 | 6.83 | 2.63 | 12.24 | 39.26 | 52.23 |
| Vetoquinol SA | 18.53bn | 1.94bn | 42.25bn | 2.48k | 21.64 | 2.28 | 14.93 | 2.28 | 4.70 | 4.70 | 44.73 | 44.53 | 0.7876 | 2.39 | 5.74 | 213,157.90 | 8.27 | 7.09 | 10.44 | 9.40 | 50.31 | 61.27 | 10.50 | 8.84 | 1.86 | -- | 0.0324 | 16.48 | -1.95 | 7.54 | 15.76 | 8.91 | 5.98 | 12.11 |
| Cosmo Pharmaceuticals NV | 3.38bn | 40.14m | 44.06bn | 325.00 | 1,007.69 | 2.70 | 80.66 | 13.02 | 0.0705 | 0.0705 | 5.94 | 26.33 | 0.1473 | 3.06 | 2.88 | 294,756.70 | 0.2051 | 0.2437 | 0.249 | 0.267 | 59.33 | 57.28 | 1.39 | 2.10 | 3.80 | 2.73 | 0.0042 | 841.86 | -5.26 | 8.07 | -93.34 | -- | 9.62 | -- |
| Fagron NV | 26.71bn | 2.47bn | 47.16bn | 3.46k | 19.04 | 2.90 | 12.48 | 1.77 | 0.9664 | 0.9664 | 10.45 | 6.35 | 0.7715 | 3.87 | 12.43 | 220,517.60 | 7.18 | 7.63 | 8.76 | 9.77 | 43.59 | 43.49 | 9.31 | 10.23 | 1.27 | 4.45 | 0.4395 | 16.28 | 11.57 | 10.10 | 1.34 | 10.48 | 19.64 | 20.11 |
| Biotest AG | 27.39bn | 6.19bn | 47.85bn | 2.43k | 9.26 | 3.10 | -- | 1.75 | 4.47 | 4.47 | 19.78 | 13.34 | 0.5936 | 1.14 | 3.83 | 322,588.60 | 13.42 | -0.0693 | 16.72 | -0.079 | 44.24 | 28.43 | 22.60 | -0.1527 | 0.9139 | 5.34 | 0.5677 | -- | 32.65 | 11.33 | 490.89 | -- | -9.36 | -- |
| Genus plc | 27.69bn | 1.37bn | 48.79bn | 3.48k | 35.54 | 2.06 | 15.38 | 1.76 | 0.5053 | 0.5053 | 10.18 | 8.71 | 0.6478 | -- | 6.03 | 193,642.10 | 2.90 | 3.58 | 3.30 | 4.20 | -- | -- | 4.47 | 5.44 | 1.40 | 5.44 | 0.3377 | 60.86 | 16.23 | 7.96 | -18.58 | 26.70 | 9.36 | 4.24 |
| Bonesupport Holding AB | 2.00bn | 812.67m | 49.85bn | 121.00 | 61.51 | 28.89 | 59.01 | 24.94 | 4.05 | 4.05 | 9.96 | 8.61 | 1.19 | 0.657 | 6.36 | 6,245,276.00 | 48.22 | -9.08 | 61.41 | -11.28 | 92.01 | 90.25 | 40.65 | -11.65 | 2.42 | -- | 0.0282 | -- | 79.76 | 43.65 | 459.44 | -- | 18.39 | -- |
Data as of May 29 2024. Currency figures normalised to EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS's reporting currency: Turkish Lira TRY
1.44%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 09 May 2024 | 5.71m | 0.83% |
| Dimensional Fund Advisors LPas of 31 Jan 2024 | 1.51m | 0.22% |
| BlackRock Advisors (UK) Ltd.as of 09 May 2024 | 545.54k | 0.08% |
| BlackRock Fund Advisorsas of 09 May 2024 | 427.75k | 0.06% |
| State Street Global Advisors Ltd.as of 09 May 2024 | 396.13k | 0.06% |
| JPMorgan Investment Management, Inc.as of 09 May 2024 | 358.98k | 0.05% |
| BlackRock Investment Management (UK) Ltd.as of 30 Apr 2024 | 307.22k | 0.05% |
| SSgA Funds Management, Inc.as of 09 May 2024 | 226.25k | 0.03% |
| Charles Schwab Investment Management, Inc.as of 09 May 2024 | 224.75k | 0.03% |
| Legal & General Investment Management Ltd.as of 28 Mar 2024 | 163.96k | 0.02% |
More ▼
Data from 31 Mar 2024 - 23 May 2024Source: FactSet Research Systems Inc.
